# The Retrospective Analysis of Multicenter Clinical Trial Data on Graft vs Host Disease in Patients Following Bone Marrow Transplantation
Placeholder: Short description of the project.

## Table of content

[Structure of repository](https://github.com/Asklepiad/GvHD/blob/main/README.md#structure-of-repository)

[Introduction](https://github.com/Asklepiad/GvHD/blob/main/README.md#introduction)

[Aims and objectives](https://github.com/Asklepiad/GvHD/blob/main/README.md#aims-and-objectives)

[Data](https://github.com/Asklepiad/GvHD/blob/main/README.md#data)

[Workflow](https://github.com/Asklepiad/GvHD/blob/main/README.md#workflow)

[Results](https://github.com/Asklepiad/GvHD/blob/main/README.md#results)

[Discussions](https://github.com/Asklepiad/GvHD/blob/main/README.md#discussions)

[Literature](https://github.com/Asklepiad/GvHD/blob/main/README.md#literature)

## Structure of repository

There are four directories in repo.

1. `raw_data`: the folder contains the data we had at the start point of analysis. You can reproduce our way of analysis (or do your own instead), using these datasets.

2. Placeholder: checking and adding data from Ivan `survival_analysis`: the folder contains one script that performed survival analysis (and, especially landmark and concurrent risks analysis).

3. `ml`: different approaches and experiments for finding predictive models for steroid resistance occurrence. There are two boosting realisations (one is R-way and another is python-way), random forest, boruta (for feature selection) and logistic regression (just for fun).

4. `cooked_data`: transformed datasets for use in further analysis

5. In main folder we can found docx file with specifications for source datasets and df_creator.rmd file that created main dataset and cooked datasets, and does EDA.

## Introduction

## Aims and objectives



## Data

## Workflow

## EDA

## Results

## Discussions

## Literature

Placeholder: Uniformity of links

> [1] Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders JE, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990 Oct 15;76(8):1464-72. PMID: 2207321.

> [2] Van Lint, M.T. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation / M.T. van Lint, C. Uderzo, A. Locasciulli, I. Majolino, R. Scimé et al. // Blood. — 1998 Oct 1. — Vol. 92, № 7. — P. 2288–2293.

> [3] Zhang MY, Zhao P, Zhang Y, Wang JS. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies. PLoS One. 2022 Jul 29;17(7):e0271979. doi: 10.1371/journal.pone.0271979. PMID: 35905125; PMCID: PMC9337651.

> [4] Park JH, Lee HJ, Kim SR, Song GW, Lee SK, Park SY, Kim KC, Hwang SH, Park JS. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Korean J Intern Med. 2014 Sep;29(5):630-6. doi: 10.3904/kjim.2014.29.5.630. Epub 2014 Aug 28. PMID: 25228839; PMCID: PMC4164727.

> [5] Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, Toubert A, Zeiser R, Galimberti S. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Front Immunol. 2020 Oct 9;11:578314. doi: 10.3389/fimmu.2020.578314. PMID: 33162993; PMCID: PMC7583636.

> [6] D’Souza, A. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides / A. D’Souza, C. Fretham — 2017. Available at: www.cibmtr.org, as of 28/07/18

> [7] Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th ed. Cham (CH): Springer; 2019. PMID: 32091673.

